189 related articles for article (PubMed ID: 24304274)
1. The role of neuroendocrine cells in prostate cancer: a comprehensive review of current literature and subsequent rationale to broaden and integrate current treatment modalities.
Lugnani F; Simone G; Biava PM; Ablin RJ
Curr Med Chem; 2014; 21(9):1082-92. PubMed ID: 24304274
[TBL] [Abstract][Full Text] [Related]
2. [Neuroendocrine differentiation in prostate cancer. An unrecognized and therapy-resistant phenotype].
Bonkhoff H; Fixemer T
Urologe A; 2004 Jul; 43(7):836-42. PubMed ID: 15048555
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells.
Yuan TC; Veeramani S; Lin MF
Endocr Relat Cancer; 2007 Sep; 14(3):531-47. PubMed ID: 17914087
[TBL] [Abstract][Full Text] [Related]
5. Reduction of two histone marks, H3k9me3 and H3k27me3 by epidrug induces neuroendocrine differentiation in prostate cancer.
Lee E; Wang J; Jung Y; Cackowski FC; Taichman RS
J Cell Biochem; 2018 Apr; 119(4):3697-3705. PubMed ID: 29236331
[TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.
Alberti C
G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine differentiation in the progression of prostate cancer.
Komiya A; Suzuki H; Imamoto T; Kamiya N; Nihei N; Naya Y; Ichikawa T; Fuse H
Int J Urol; 2009 Jan; 16(1):37-44. PubMed ID: 19120524
[TBL] [Abstract][Full Text] [Related]
8. De novo large cell neuroendocrine carcinoma of the prostate gland with pelvic lymph node metastasis: a case report with review of literature.
Okoye E; Choi EK; Divatia M; Miles BJ; Ayala AG; Ro JY
Int J Clin Exp Pathol; 2014; 7(12):9061-6. PubMed ID: 25674288
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of manganese superoxide dismutase (SOD2) is a common pathway for neuroendocrine differentiation in prostate cancer cells.
Quirós I; Sáinz RM; Hevia D; García-Suárez O; Astudillo A; Rivas M; Mayo JC
Int J Cancer; 2009 Oct; 125(7):1497-504. PubMed ID: 19507253
[TBL] [Abstract][Full Text] [Related]
10. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
11. Biological effect of neoadjuvant androgen-deprivation therapy assessed on specimens from radical prostatectomy: a systematic review.
Antonelli A; Palumbo C; Veccia A; Grisanti S; Triggiani L; Zamboni S; Furlan M; Simeone C; Magrini S; Berruti A
Minerva Urol Nefrol; 2018 Aug; 70(4):370-379. PubMed ID: 29392925
[TBL] [Abstract][Full Text] [Related]
12. Prostate carcinoma with amphicrine features: further refining the spectrum of neuroendocrine differentiation in tumours of primary prostatic origin?
Prendeville S; Al-Bozom I; Compérat E; Sweet J; Evans AJ; Ben-Gashir M; Mete O; van der Kwast TH; Downes MR
Histopathology; 2017 Dec; 71(6):926-933. PubMed ID: 28756619
[TBL] [Abstract][Full Text] [Related]
13. Salvage cryoablation for locally recurrent prostate cancer following primary radiotherapy.
Mouraviev V; Spiess PE; Jones JS
Eur Urol; 2012 Jun; 61(6):1204-11. PubMed ID: 22421081
[TBL] [Abstract][Full Text] [Related]
14. Neuroendocrine differentiation in the setting of prostatic carcinoma: contemporary assessment of a consecutive series.
Gopalan A; Al-Ahmadie H; Chen YB; Sarungbam J; Sirintrapun SJ; Tickoo SK; Reuter VE; Fine SW
Histopathology; 2022 Aug; 81(2):246-254. PubMed ID: 35758203
[TBL] [Abstract][Full Text] [Related]
15. Genomic Markers in Prostate Cancer Decision Making.
Cucchiara V; Cooperberg MR; Dall'Era M; Lin DW; Montorsi F; Schalken JA; Evans CP
Eur Urol; 2018 Apr; 73(4):572-582. PubMed ID: 29129398
[TBL] [Abstract][Full Text] [Related]
16. Prognostic effect of neuroendocrine differentiation in prostate cancer: A critical review.
Surcel CI; van Oort IM; Sooriakumaran P; Briganti A; De Visschere PJ; Fütterer JJ; Ghadjar P; Isbarn H; Ost P; van den Bergh RC; Yossepowitch O; Giannarini G; Ploussard G;
Urol Oncol; 2015 Jun; 33(6):265.e1-7. PubMed ID: 25238700
[TBL] [Abstract][Full Text] [Related]
17. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.
Cussenot O; Villette JM; Cochand-Priollet B; Berthon P
Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663
[TBL] [Abstract][Full Text] [Related]
18. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities.
Eggener SE; Scardino PT; Carroll PR; Zelefsky MJ; Sartor O; Hricak H; Wheeler TM; Fine SW; Trachtenberg J; Rubin MA; Ohori M; Kuroiwa K; Rossignol M; Abenhaim L;
J Urol; 2007 Dec; 178(6):2260-7. PubMed ID: 17936815
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation of neuroendocrine differentiation in prostate cancer after androgen deprivation therapy, degree and androgen independence.
Ito T; Yamamoto S; Ohno Y; Namiki K; Aizawa T; Akiyama A; Tachibana M
Oncol Rep; 2001; 8(6):1221-4. PubMed ID: 11605036
[TBL] [Abstract][Full Text] [Related]
20. Debulking surgery in the setting of very high-risk prostate cancer scenarios.
Oderda M; Joniau S; Spahn M; Gontero P
BJU Int; 2012 Sep; 110(6 Pt B):E192-8. PubMed ID: 22313515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
